Cantor Fitzgerald Issues Negative Forecast for ABOS Earnings

Key Points

• Cantor Fitzgerald has revised its earnings per share (EPS) estimate for Acumen Pharmaceuticals for FY2025, projecting a loss of ($2.29), down from a previous estimate of ($1.92), highlighting a significant reduction in expectations.
• Acumen Pharmaceuticals reported a quarterly EPS of ($0.68), which missed analysts' expectations of ($0.54) by ($0.14).
• Citigroup has initiated coverage on Acumen Pharmaceuticals with a "buy" rating and set a price target of $4.00 for the stock.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Acumen Pharmaceuticals in a research report issued on Wednesday, August 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($2.29) per share for the year, down from their previous forecast of ($1.92). The consensus estimate for Acumen Pharmaceuticals' current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Acumen Pharmaceuticals' FY2026 earnings at ($1.45) EPS.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.14).

Separately, Citigroup assumed coverage on shares of Acumen Pharmaceuticals in a report on Tuesday, June 17th. They issued a "buy" rating and a $4.00 price target on the stock.

Acumen Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:ABOS traded up $0.01 during trading on Friday, reaching $1.41. The stock had a trading volume of 37,052 shares, compared to its average volume of 332,396. Acumen Pharmaceuticals has a one year low of $0.86 and a one year high of $3.36. The company has a market capitalization of $85.10 million, a P/E ratio of -0.62 and a beta of 0.14. The company has a current ratio of 5.97, a quick ratio of 8.02 and a debt-to-equity ratio of 0.26. The firm's 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.22.

Institutional Trading of Acumen Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC acquired a new stake in Acumen Pharmaceuticals in the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC boosted its stake in Acumen Pharmaceuticals by 427.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company's stock worth $35,000 after purchasing an additional 16,714 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Acumen Pharmaceuticals during the 1st quarter valued at approximately $46,000. Jane Street Group LLC lifted its stake in Acumen Pharmaceuticals by 116.1% during the 4th quarter. Jane Street Group LLC now owns 30,740 shares of the company's stock valued at $53,000 after acquiring an additional 221,144 shares during the period. Finally, Qube Research & Technologies Ltd lifted its stake in Acumen Pharmaceuticals by 160.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after acquiring an additional 35,424 shares during the period. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.